Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Sledge

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Breast (Edinburgh, Scotland)|August 21, 2007
Angiogenesis as targeted breast cancer therapyDaniel F Hayes, Kathy Miller, George Sledge
Breast Cancer Research and Treatment|August 28, 2022
Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancerTanya Gupta, Natasha Purington, Mina Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancerKathy D Miller, Jose Manuel Trigo, Catherine Wheeler, et al.
JCO Precision Oncology|September 14, 2020
Susan G. Komen Big Data for Breast Cancer Initiative: How Patient Advocacy Organizations Can Facilitate Using Big Data to Improve Patient OutcomesJerome Jourquin, Stephanie Birkey Reffey, Cheryl Jernigan, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 13, 2005
A phase II study of methylphenidate for the treatment of fatigueAmy Hanna, George Sledge, Mary Lou Mayer, et al.
Nature Reviews. Cancer|March 27, 2007
Shaping the future of biomarker research in breast cancer to ensure clinical relevanceM Carolina Hinestrosa, Kay Dickersin, Pamela Klein, et al.
Journal of Psychosocial Oncology|November 9, 2010
An intervention to improve communication between breast cancer survivors and their physiciansCleveland G Shields, Kim Wagler Ziner, Sara A Bourff, et al.
JAMA Oncology|February 2, 2023
Breast Cancer Diagnosis, Treatment, and Outcomes of Patients From Sex and Gender Minority GroupsErik Eckhert, Olivia Lansinger, Victor Ritter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancerKimberly L Blackwell, Harold J Burstein, Anna Maria Storniolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2012
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 StudyKimberly L Blackwell, Harold J Burstein, Anna Maria Storniolo, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Breast (Edinburgh, Scotland)|August 21, 2007
Angiogenesis as targeted breast cancer therapyDaniel F Hayes, Kathy Miller, George Sledge
Breast Cancer Research and Treatment|August 28, 2022
Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancerTanya Gupta, Natasha Purington, Mina Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancerKathy D Miller, Jose Manuel Trigo, Catherine Wheeler, et al.
JCO Precision Oncology|September 14, 2020
Susan G. Komen Big Data for Breast Cancer Initiative: How Patient Advocacy Organizations Can Facilitate Using Big Data to Improve Patient OutcomesJerome Jourquin, Stephanie Birkey Reffey, Cheryl Jernigan, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 13, 2005
A phase II study of methylphenidate for the treatment of fatigueAmy Hanna, George Sledge, Mary Lou Mayer, et al.
Nature Reviews. Cancer|March 27, 2007
Shaping the future of biomarker research in breast cancer to ensure clinical relevanceM Carolina Hinestrosa, Kay Dickersin, Pamela Klein, et al.
Journal of Psychosocial Oncology|November 9, 2010
An intervention to improve communication between breast cancer survivors and their physiciansCleveland G Shields, Kim Wagler Ziner, Sara A Bourff, et al.
JAMA Oncology|February 2, 2023
Breast Cancer Diagnosis, Treatment, and Outcomes of Patients From Sex and Gender Minority GroupsErik Eckhert, Olivia Lansinger, Victor Ritter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancerKimberly L Blackwell, Harold J Burstein, Anna Maria Storniolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2012
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 StudyKimberly L Blackwell, Harold J Burstein, Anna Maria Storniolo, et al.
Pageof 4